ArticleNature medicine2021
Has SARS-CoV-2 reached peak fitness?
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Biophysical principles predict fitness of SARS-CoV-2 variants.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Biophysical principles predict fitness of SARS-CoV-2 variants.bioRxiv : the preprint server for biology · 2024Article
- Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry.Cell reports · 2022Article
- Review
- Equitable access to COVID-19 vaccines makes a life-saving difference to all countries.Nature human behaviour · 2022Article
- COVID-19 vaccine strategies must focus on severe disease and global equity.Lancet (London, England) · 2022Review
- Rethinking COVID-19 vaccine allocation: it is time to care about our neighbours.The Lancet regional health. Europe · 2022Article
- Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials.Frontiers in pharmacology · 2022Article
- Perspectives: SARS-CoV-2 Spike Convergent Evolution as a Guide to Explore Adaptive Advantage.Frontiers in cellular and infection microbiology · 2022Article
- SARS-CoV-2 mutational cascades and the risk of hyper-exponential growth.Microbial pathogenesis · 2021Article
- SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Vaccine nationalism and the dynamics and control of SARS-CoV-2.Science (New York, N.Y.) · 2021Article
- We should not dismiss the possibility of eradicating COVID-19: comparisons with smallpox and polio.BMJ global health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34155413What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.